PubRank

Fiorella D'Auria

Author PubWeight™ 19.95‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res 2010 1.11
2 Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res 2013 1.09
3 Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res 2008 1.03
4 Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment? J Clin Oncol 2012 1.01
5 Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res 2013 0.98
6 Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 2009 0.95
7 A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol 2012 0.94
8 Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol 2012 0.92
9 Cytological and histological detection of amyloid deposits in bone marrow of patients affected by multiple myeloma. Leuk Lymphoma 2011 0.86
10 Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes. Leuk Res 2009 0.84
11 Primary plasma cell leukemia in the era of new drugs: has something changed? Crit Rev Oncol Hematol 2011 0.84
12 Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. Leuk Res 2010 0.83
13 Amyloid in bone marrow smears of patients affected by multiple myeloma. Ann Hematol 2009 0.82
14 Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature. Leuk Res 2007 0.82
15 Melphalan: old and new uses of a still master drug for multiple myeloma. Expert Opin Investig Drugs 2007 0.81
16 Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases. Mediterr J Hematol Infect Dis 2012 0.81
17 Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander? Am J Blood Res 2013 0.80
18 Role of thalidomide in previously untreated patients with multiple myeloma. Expert Rev Anticancer Ther 2008 0.78
19 Employment of oligodeoxynucleotide plus interleukin-2 improves cytogenetic analysis in splenic marginal zone lymphoma. J Biomed Biotechnol 2011 0.77
20 First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective. Curr Drug Targets 2009 0.76
21 Validation of vacuum-based refrigerated system for biobanking tissue preservation: analysis of cellular morphology, protein stability, and RNA quality. Biopreserv Biobank 2014 0.76
22 An urologic face of chronic lymphocytic leukemia: sequential prostatic and penis localization. Mediterr J Hematol Infect Dis 2013 0.76
23 Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia. Clin Ther 2010 0.75
24 The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders. Expert Opin Biol Ther 2011 0.75
25 Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia. Br J Haematol 2012 0.75